DOCSLIB.ORG

IMEMR Current Contents March 2007 Vol.6 No.1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IMEMR Current Contents March 2007 Vol.6 No.1 Index Medicus for the WHO Eastern Mediterranean Region with Abstracts IMEMR Current Contents March 2007 Vol.6 No.1 Table of Contents IMEMR Current Contents ................................................................. i Subjects Index ............................................................................. 1 Abscess ..........................................................................................................................................3 Adenomatous Polyposis Coli..........................................................................................................3 Adolescent......................................................................................................................................3 Adrenal Hyperplasia, Congenital....................................................................................................4 Aortic Aneurysm .............................................................................................................................4 Arthritis, Infectious ..........................................................................................................................4 Astigmatism....................................................................................................................................4 Bacteremia .....................................................................................................................................5 Bioethics .........................................................................................................................................5 Biomedical Research......................................................................................................................6 Bladder ...........................................................................................................................................7 Bladder Fistula................................................................................................................................7 Blepharitis.......................................................................................................................................7 Blindness ........................................................................................................................................8 Bone Density ..................................................................................................................................8 Bone Marrow Cells .........................................................................................................................8 Boraginaceae .................................................................................................................................9 Breast Diseases .............................................................................................................................9 Breast Feeding ...............................................................................................................................9 Breast Neoplasms ........................................................................................................................10 Bronchopulmonary Sequestration ................................................................................................12 Brucellosis ....................................................................................................................................13 Carcinoma, Hepatocellular ...........................................................................................................13 Cardiomyopathy, Dilated ..............................................................................................................14 Cardiopulmonary Resuscitation....................................................................................................14 Cardiovascular Diseases..............................................................................................................14 Catheterization, Central Venous...................................................................................................14 Cause of Death.............................................................................................................................15 Caustics........................................................................................................................................15 CD4 Lymphocyte Count ...............................................................................................................15 Cerebrovascular Accident ............................................................................................................16 Child Welfare ................................................................................................................................20 Chlorpromazine ............................................................................................................................20 Cholecystitis, Acute ......................................................................................................................21 Colon ............................................................................................................................................21 Colon, Transverse ........................................................................................................................21 Colorectal Neoplasms ..................................................................................................................22 Community Health Services .........................................................................................................22 Community-Acquired Infections....................................................................................................22 Contact Lenses.............................................................................................................................23 Contraceptives,Oral,Combined ....................................................................................................23 Corneal Transplantation ...............................................................................................................23 Corneal Ulcer................................................................................................................................24 Coronary Angiography..................................................................................................................24 Coronary Disease.........................................................................................................................24 Counseling....................................................................................................................................24 Critical Care..................................................................................................................................25 Cross Infection..............................................................................................................................25 Cryptorchidism..............................................................................................................................25 Dental Caries................................................................................................................................26 Dental Health Surveys..................................................................................................................26 Depression ...................................................................................................................................27 Dermatofibrosarcoma ...................................................................................................................27 Diabetes Complications................................................................................................................27 Diabetes Mellitus ..........................................................................................................................28 Diabetes Mellitus, Type 1 .............................................................................................................28 Diabetes Mellitus, Type 2 .............................................................................................................29 Diabetic Nephropathies ................................................................................................................30 Dialysis Solutions .........................................................................................................................30 Diskectomy ...................................................................................................................................31 Drug Industry ................................................................................................................................31 Dysmenorrhea ..............................................................................................................................31 Echinococcosis.............................................................................................................................32 Electrocardiography......................................................................................................................33 Epidermolysis Bullosa ..................................................................................................................33 Escherichia coli Infections ............................................................................................................33
Load more

Recommended publications
  • WO 2015/048577 A2 April 2015 (02.04.2015) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/048577 A2 April 2015 (02.04.2015) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 48/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US20 14/057905 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 26 September 2014 (26.09.2014) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/883,925 27 September 2013 (27.09.2013) US (84) Designated States (unless otherwise indicated, for every 61/898,043 31 October 2013 (3 1. 10.2013) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: EDITAS MEDICINE, INC.
    [Show full text]
  • Metabolic Cutis Laxa Syndromes
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector J Inherit Metab Dis (2011) 34:907–916 DOI 10.1007/s10545-011-9305-9 CDG - AN UPDATE Metabolic cutis laxa syndromes Miski Mohamed & Dorus Kouwenberg & Thatjana Gardeitchik & Uwe Kornak & Ron A. Wevers & Eva Morava Received: 28 October 2010 /Revised: 11 February 2011 /Accepted: 17 February 2011 /Published online: 23 March 2011 # The Author(s) 2011. This article is published with open access at Springerlink.com Abstract Cutis laxa is a rare skin disorder characterized by Disorders of Glycosylation (CDG). Since then several wrinkled, redundant, inelastic and sagging skin due to inborn errors of metabolism with cutis laxa have been defective synthesis of elastic fibers and other proteins of the described with variable severity. These include P5CS, extracellular matrix. Wrinkled, inelastic skin occurs in ATP6V0A2-CDG and PYCR1 defects. In spite of the many cases as an acquired condition. Syndromic forms of evolving number of cutis laxa-related diseases a large part cutis laxa, however, are caused by diverse genetic defects, of the cases remain genetically unsolved. In metabolic cutis mostly coding for structural extracellular matrix proteins. laxa syndromes the clinical and laboratory features might Surprisingly a number of metabolic disorders have been partially overlap, however there are some distinct, discrim- also found to be associated with inherited cutis laxa. inative features. In this review on metabolic diseases Menkes disease was the first metabolic disease reported causing cutis laxa we offer a practical approach for the with old-looking, wrinkled skin.
    [Show full text]
  • Discriminative Features in Three Autosomal Recessive Cutis Laxa Syndromes: Cutis Laxa IIA, Cutis Laxa IIB, and Geroderma Osteoplastica
    International Journal of Molecular Sciences Review Discriminative Features in Three Autosomal Recessive Cutis Laxa Syndromes: Cutis Laxa IIA, Cutis Laxa IIB, and Geroderma Osteoplastica Ariana Kariminejad 1,*, Fariba Afroozan 1, Bita Bozorgmehr 1, Alireza Ghanadan 2,3, Susan Akbaroghli 4, Hamid Reza Khorram Khorshid 5, Faezeh Mojahedi 6, Aria Setoodeh 7, Abigail Loh 8, Yu Xuan Tan 8, Nathalie Escande-Beillard 8, Fransiska Malfait 9, Bruno Reversade 8, Thatjana Gardeitchik 10 and Eva Morava 10,11 1 Kariminejad-Najmabadi Pathology & Genetics Center, #2, 4th Street, Hasan Seyf Street, Sanat Square, Tehran 14667-13713, Iran; [email protected] (F.A.); [email protected] (B.B.) 2 Department of Dermatopathology, Razi Dermatology Hospital, Tehran University of Medical Sciences, Tehran 14167-53955, Iran; [email protected] 3 Department of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran 14197-33141, Iran 4 Clinical Genetics Division, Mofid Children’s Hospital, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 15514-15468, Iran; [email protected] 5 Genetic Research Centre, University of Social Welfare and Rehabilitation Sciences, Tehran 19857-13834, Iran; [email protected] 6 Mashhad Medical Genetic Counseling Center, Social Welfare and Rehabilitation Organization, Mashhad 91767-61999, Iran; [email protected] 7 Division of Pediatric Endocrinology and Inherited Metabolic Disorders, Department of Pediatrics, Tehran University of Medical Sciences, Tehran
    [Show full text]
  • Blueprint Genetics Congenital Disorders of Glycosylation Panel
    Congenital Disorders of Glycosylation Panel Test code: ME1901 Is a 48 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of a congenital disorder of N-linked glycosylation or combined defects of glycosylation affecting both the N-linked and O-linked glycosylation pathways. The genes on this panel are included in the Comprehensive Metabolism Panel. About Congenital Disorders of Glycosylation Most subtypes of congenital disorders of glycosylation (CDG) are classified as disorders of N-glycosylation, which involves carbohydrates called N-linked oligosaccharides. These oligosaccharides are created in a specific order to create specific sugar trees, which are then attached to proteins on various cells. Disorders of N-glycosylation are due to an enzyme deficiency or other malfunction somewhere along the N-glycosylation pathway. There are 42 different enzymes in the pathway; any of them may be mutated and cause a disorder belonging to this group. Different mutated enzymes cause different phenotypes. Congenital disorders of N-linked glycosylation are a genetically and phenotypically heterogeneous group of diseases. Most commonly, symptoms begin in early infancy. Manifestations range from mild to severe, involving only protein-losing enteropathy and hypoglycemia or severe intellectual disability with malfunction of several organs. Sometimes the disorder may be fatal. Most patients require nutritional supplements. Most of the individual disorders have been observed only in a very limited number of patients. The most common ones are PMM2-related disorder (approximately 700 patients reported), MPI-related disorder (>20 patients) and ALG6-related disorder (>30 patients). Other types of disorder are extremely rare.
    [Show full text]
  • Global Journal of Medical Research: K I Nterdisciplinary
    Online ISSN : 2249-4618 Print ISSN : 0975-5888 DOI : 10.17406/GJMRA Bafqs Miners Burnout Elevated Nutritional Needs Thérapeutiques Et Pronostiques Professional Community Training VOLUME 16 ISSUE 4 VERSION 1.0 Global Journal of Medical Research: k Interdisciplinary Global Journal of Medical Research: k Interdisciplinary Volume 16 Issue 4 (Ver. 1.0) Open Association of Research Society © Global Journal of Medical Global Journals Inc. Research . 2016. (A Delaware USA Incorporation with “Good Standing”; Reg. Number: 0423089) Sponsors:Open Association of Research Society All rights reserved. Open Scientific Standards This is a special issue published in version 1.0 Publisher’s Headquarters office of “Global Journal of Medical Research.” By Global Journals Inc. Global Journals ® Headquarters All articles are open access articles distributed 945th Concord Streets, under “Global Journal of Medical Research” Framingham Massachusetts Pin: 01701, Reading License, which permits restricted use. United States of America Entire contents are copyright by of “Global USA Toll Free: +001-888-839-7392 Journal of Medical Research” unless otherwise noted on specific articles. USA Toll Free Fax: +001-888-839-7392 No part of this publication may be reproduced Offset Typesetting or transmitted in any form or by any means, electronic or mechanical, including Global Journals Incorporated photocopy, recording, or any information storage and retrieval system, without written 2nd, Lansdowne, Lansdowne Rd., Croydon-Surrey, permission. Pin: CR9 2ER, United Kingdom The opinions and statements made in this book are those of the authors concerned. Packaging & Continental Dispatching Ultraculture has not verified and neither confirms nor denies any of the foregoing and Global Journals no warranty or fitness is implied.
    [Show full text]
  • Congenital Disorders of Glycosylation Precision Panel Overview
    Congenital Disorders of Glycosylation Precision Panel Overview Congenital Disorders of Glycosylation (CDG) are a group of rapidly expanding metabolic disorders that arise due to abnormal protein or lipid glycosylation. There are difficulties trying to diagnose them because they broadly affect many organs and functions, demonstrating a clinical heterogeneity. These phenotypically diverse disorders present as clinical syndromes affecting multiple systems including the central nervous system, muscle function, transport, regulation, immunity, endocrine system, and coagulation. Over 150 different CDGs have been and those affecting N-glycosylation are the most common type. The Igenomix Congenital Disorders of Glycosylation Precision Panel can be used to make an accurate and directed diagnosis ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next- generation sequencing (NGS) to fully understand the spectrum of relevant genes involved. Indications The Igenomix Congenital Disorders of Glycosylation Precision Panel is indicated for those patients with a clinical suspicion or diagnosis with or without the following manifestations: - Low muscle tone or floppiness - Failure to thrive - Gross developmental delay - Liver disease - Abnormal bleeding or blood clotting - Misaligned or crossed eyes - Seizures - Stroke-like episodes Clinical Utility The clinical utility of this panel is: - The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient. - Early initiation of treatment with a multidisciplinary team in the form of nutritional therapy, transplantation, activated sugars, gene therapy and pharmacological chaperones. 1 - Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. - Improvement of delineation of genotype-phenotype correlation given the clinical and genetically heterogenous profile of CDGs.
    [Show full text]
  • ATP6V0A2 Gene Atpase H+ Transporting V0 Subunit A2
    ATP6V0A2 gene ATPase H+ transporting V0 subunit a2 Normal Function The ATP6V0A2 gene provides instructions for making one part, the a2 subunit, of a large protein complex (a group of proteins that work together). This protein complex is known as a vacuolar H+-ATPase (V-ATPase). A V-ATPase acts as a pump to move positively charged hydrogen atoms (protons) across cell membranes. V-ATPases are embedded in the membranes surrounding cells, where they transport protons into and out of cells. This movement of protons helps regulate the relative acidity (pH) of cells and their surrounding environment. Tight control of pH is necessary for most biological reactions to proceed properly. Within cells, V-ATPases help regulate the pH of particular cell compartments. These compartments include endosomes and lysosomes, which digest and recycle materials that the cell no longer needs. Studies suggest that V-ATPases are also involved in the movement (trafficking) of small sac-like structures called vesicles. Vesicles transport many types of molecules within cells. V-ATPases also play a key role in a complex process called glycosylation, in which proteins are modified by adding sugar molecules. Glycosylation is necessary for the normal function of many different kinds of proteins. V-ATPases regulate the pH of a cellular structure called the Golgi apparatus, where glycosylation occurs. Health Conditions Related to Genetic Changes Cutis laxa More than 40 variants (also known as mutations) in the ATP6V0A2 gene have been identified in people with cutis laxa. ATP6V0A2 variants cause a form of the disorder called autosomal recessive cutis laxa type 2A (ARCL2A), which is characterized by loose, sagging skin; distinctive facial features; and larger than normal spaces ( fontanelles) between the skull bones that close later than usual.
    [Show full text]
  • Hereditary Disorders of Connective Tissue: a Guide to the Emerging Differential Diagnosis Maureen Murphy-Ryan, BS1, Apostolos Psychogios, MD2, and Noralane M
    ARTICLE Hereditary disorders of connective tissue: A guide to the emerging differential diagnosis Maureen Murphy-Ryan, BS1, Apostolos Psychogios, MD2, and Noralane M. Lindor, MD2 Purpose: To create a practical desk reference for clinicians focused each element. Proteins that modify these component elements— 7 on the differential diagnosis of individuals presenting with features such as the metalloproteinases and lysyl hydroxylase 3, which that suggest an inherited disorder of connective tissue. Methods: We act on the structure of collagen fibers, and homocysteine, which searched the medical literature for distinct clinical entities that can affect the integrity of fibrillin in elastic tissues—have also shared clinical features with Marfan syndrome and other classical been implicated in disorders of connective tissue. In addition, inherited disorders of connective tissue. Results: Thirty-six distinct mutations in genes that affect protein glycosylation are also heritable disorders of connective tissue were identified that have implicated in the differential diagnosis of connective tissue overlapping features. These disorders were organized into two ma- disorders. Because each of these elements contribute to connec- trices according to clinical characteristics and according to causative tive tissue structure in a number of different body locations, genes. Conclusions: A broad differential diagnosis is emerging for genetic defects in a single connective tissue component may individuals presenting with features suggestive of altered connective manifest in more than one organ in the body (pleiotropy). This tissue. Recent advances in molecular genetics have aided in the results in clinically overlapping multisystemic findings that may delineation of these disorders. Genet Med 2010:12(6):344–354. make diagnosis of a specific entity especially challenging.
    [Show full text]
  • Congenital Cutis Laxa
    Congenital Cutis Laxa Congenital cutis laxa is a rare inherited connective tissue iv. A broad flat nose disorder manifested by inelastic, loose, pendulous skin, giving v. Sagging cheeks the appearance of premature aging. vi. Long upper lip vii. Short columella GENETICS/BASIC DEFECTS viii. Large ears e. Skin 1. Genetic heterogeneity i. Prominent skin folds (loose skin) around the a. Autosomal recessive cutis laxa: the most common knees, abdomen, and thighs type ii. No hyperelasticity, fragility, or difficulty in wound i. Type I autosomal recessive cutis laxa: less fre- healing quent than type II f. Skeletal muscular abnormalities ii. Type II autosomal recessive cutis laxa i. Dislocation of the hips b. Autosomal dominant cutis laxa ii. Joint hyperextensibility c. X-liked recessive cutis laxa iii. Hernia i. Previously called occipital horn syndrome iv. Osteoporosis ii. At present, best termed as Ehlers-Danlos syn- g. Cardiopulmonary abnormalities drome type IX i. Severe pulmonary emphysema resulting from 2. Biochemical and molecular defects generalized elastolysis a. Autosomal recessive cutis laxa type I: molecular studies a) Tachypnea in a large consanguineous Turkish family demon- b) Pneumonitis strated the presence of a homozygous missense muta- c) Airway obstruction tion (T998C) in the fibulin-5 (FBLN5) gene, resulting d) Severe hypoxia in a serine-to-proline (S227P) substitution in the e) Respiratory failure fourth calcium-binding epidermal growth factor-like ii. Cardiac abnormalities domain of fibulin-5 protein a) Right ventricular enlargement b. Autosomal dominant cutis laxa b) Cor pulmonale i. Can be caused by mutations in the elastin gene c) Bundle branch block ii. Molecular heterogeneity cannot be excluded d) Pulmonary artery hypoplasia and stenosis c.
    [Show full text]
  • IMMUNE FUNCTION in ATP6V0A2-RELATED CUTIS LAXA by Michelle Morrow BS, the Ohio State University, 1992 Phd, Northwestern Universi
    IMMUNE FUNCTION IN ATP6V0A2-RELATED CUTIS LAXA by Michelle Morrow BS, The Ohio State University, 1992 PhD, Northwestern University, 2005 Submitted to the Graduate Faculty of the Department of Human Genetics Graduate School of Public Health in partial fulfillment of the requirements for the degree of Master of Science University of Pittsburgh 2017 UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH This thesis was presented by Michelle Morrow It was defended on April 19, 2017 and approved by Adrea L. Durst, MS, DrPH, LCGC, Assistant Professor, Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh Louise D’Cruz, PhD, Assistant Professor, Department of Immunology, School of Medicine, University of Pittsburgh Thesis Director: Zsolt Urban, PhD, Associate Professor, Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh ii Copyright © by Michelle Morrow 2017 iii Zsolt Urban, PhD IMMUNE FUNCTION IN ATP6V0A2-RELATED CUTIS LAXA Michelle Morrow, MS University of Pittsburgh, 2017 ABSTRACT Cutis laxa (CL) is a genetic disorder of connective tissue. CL has known effects on multiple body systems, but its relationship to immune function has not been characterized. Recently, the laboratory of Jordan Orange, MD, PhD identified a patient with immune deficiency disease who also had a mutation in a known CL-causing gene, ATP6V0A2. This observation prompted us to look for evidence of immune dysfunction among individuals with ATP6V0A2- related CL. We administered an infection history survey to study participants with ATP6V0A2- related CL, their unaffected relatives, and individuals with ELN-related CL. We calculated a novel age weighted infection score for each participant and compared the three groups.
    [Show full text]
  • Genetic Molecular Basis of Cutis Laxa and Surgical Management
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 14, Issue 10 Ver. VIII (Oct. 2015), PP 32-41 www.iosrjournals.org Genetic Molecular Basis of Cutis Laxa and Surgical Management Dr.N.Mariappan1, Dr.Subha Dhua2, Dr.Sanket Shetty3, Dr.D.R.Shekar4 1,2Associate professor of Plastic Surgery, 3Postgraguate in plastic surgery, 4Professor and HOD, Department of Plastic and Reconstructive Surgery, Vydehi Institute of Medical sciences and Research centre, Bengaluru, India. Abstract: Cutis laxa is a rare condition involving the skin. There is loss of resilience, texture and quality of skin. The inherited form of cutis laxa is rather uncommon. Some 400 families have been reported in literature until now. The majority of the various subtypes of cutis laxa syndromes affect connective tissue development through structural gene defects. In most of the patients there is a strong histological evidence demonstrating an abnormal structure of elastin fibers and the associated extracellular matrix network of the skin.[1]Recently autosomal recessive cutis laxa syndrome type II(ARCL II; MIM 219200) emerged in the center of attention, due to the discovery of a unique underlying metabolic etiology.[2]This novel inborn error is a distinct form of the Congenital Disorders of Glycosylation (CDG). The defect is responsible for the phenotype in several patients diagnosed with the most common and viable form of the cutis laxa. Elastin gene mutations have been associated with a variety of phenotypes. Autosomal dominant cutis laxa (ACDL) is a rare disorder that presents with lax skin, typical facial characteristics, inguinal hernias, aortic root dilatation and pulmonary emphysema.
    [Show full text]
  • A Case of Gerodermia Osteodysplastica Diagnosed by Recurrent Pathologic Fractures
    Elmer ress Case Report J Endocrinol Metab. 2014;4(5-6):151-152 A Case of Gerodermia Osteodysplastica Diagnosed by Recurrent Pathologic Fractures Mussa H. Almalkia, b, d, Fahad Alshahranic Abstract Case Report Gerodermia osteodysplastica (GO) is a rare autosomal recessive dis- A 33-year-old female patient of healthy Saudi parents in a con- order. We report the case of a 33-year-old patient with GO, with gen- sanguineous marriage (parents were first cousins) was born eralized osteoporosis and frequent spontaneous fractures. We should by normal delivery after an uneventful pregnancy. The patient consider this condition in the differential diagnosis of a patient with had multiple spontaneous fractures of the lower extremities frequent spontaneous fractures. between 3 and 12 years of age, which were treated conserva- tively, with subsequent limitation of her physical activity. Al- Keywords: Gerodermia osteodysplastica; Osteoporosis; Fracture; though she had multiple fractures, no diagnosis or treatment Bisphosphonate was provided until she was 14 years old, when she sustained a severe displaced fracture of the right femur that was fixed surgically. Her face appeared aged with a prominent forehead, Introduction low set posteriorly rotated ears, sagging cheeks, and short neck. Gerodermia osteodysplastica (GO) is a rare autosomal reces- The patient’s skin was lax, wrinkled mainly over the dor- sive connective tissue disorder first described by Bamatter et sum of the hands and feet, and she had an atrophic, band-like al (1950) in five members of a Swiss family [1]. Fewer than 35 skin lesion on her forehead extending posteriorly to the scalp patients have been reported to date [2].
    [Show full text]